Alzheimer’s disease has a strong genetic component, with twin studies estimating that about 70% of the overall risk is heritable. But “genetic” doesn’t mean “guaranteed.” For the vast majority of people, Alzheimer’s results from a complex mix of genetic susceptibility and environmental factors, not a single inherited mutation. Less than 1% of all Alzheimer’s cases are caused by a gene that virtually guarantees the disease.
Two Types of Genetic Risk
Genetics influence Alzheimer’s in two fundamentally different ways, and understanding the distinction matters. The first is deterministic: a small number of gene mutations directly cause the disease, almost always before age 65. The second is probabilistic: certain gene variants raise or lower your likelihood of developing Alzheimer’s but never make it certain. Most people asking whether Alzheimer’s “runs in the family” are dealing with the second type.
Early-Onset Alzheimer’s and Inherited Mutations
Fewer than 1% of Alzheimer’s cases follow an autosomal dominant pattern, meaning a single copy of a mutated gene inherited from one parent is enough to cause the disease. These mutations sit on three genes: PSEN1, APP, and PSEN2. If a parent carries one of these mutations, each child has a 50% chance of inheriting it, and those who do will almost certainly develop Alzheimer’s, typically between their 30s and early 60s.
PSEN1 is the most commonly involved gene, with over 220 known disease-causing mutations. APP has about 32, and PSEN2 has around 19. All three genes affect the same biological pathway. They either increase the total production of a sticky protein fragment called amyloid-beta or cause the body to produce a version of it that clumps together more easily. That clumping in the brain is the hallmark of Alzheimer’s pathology.
Because these mutations are so rare, genetic testing for them is only recommended in specific situations: when someone develops symptoms before age 65 and has a family history of dementia, when a family shows an autosomal dominant inheritance pattern, or when a relative has already tested positive for one of these mutations. Testing should happen with a genetic counselor who can help interpret the results and their implications for the family.
The APOE Gene and Late-Onset Risk
For the more common form of Alzheimer’s, which appears after age 65, the single most influential genetic factor is a gene called APOE. Everyone carries two copies of it, and it comes in three main variants: e2, e3, and e4. The combination you inherit significantly shifts your lifetime risk.
People with no copies of the e4 variant have roughly a 20% lifetime risk of developing Alzheimer’s. Carrying one copy of e4 raises that to about 47%. Carrying two copies pushes it to around 91%. That’s a dramatic increase, but it’s still not 100%, and plenty of people with one e4 copy never develop the disease. The e4 variant is common: about 25% of the population carries at least one copy.
On the protective side, the e2 variant meaningfully reduces risk. In a study of autopsy-confirmed cases, people with two copies of e2 had an 87% lower risk than those with two copies of e3 (the most common variant) and a 99.6% lower risk compared to those with two copies of e4. Even one copy of e2 offers some protection.
Despite the strong statistical associations, clinical guidelines from the American College of Medical Genetics advise against using APOE testing to predict Alzheimer’s in healthy people. The reason: the results don’t change medical management, and the predictive value for any individual is limited. Carrying e4 doesn’t mean you’ll get Alzheimer’s, and not carrying it doesn’t mean you won’t. Direct-to-consumer genetic tests that report APOE status are specifically discouraged by professional guidelines because interpreting the results without genetic counseling can cause unnecessary anxiety or false reassurance.
Beyond APOE: Other Risk Genes
Researchers have identified dozens of other gene variants that each contribute a small amount to Alzheimer’s risk. Three of the most significant are TREM2, SORL1, and ABCA7. Rare damaging variants in these genes have a strong enough association with early-onset Alzheimer’s to reach the highest level of statistical confidence in large genetic studies.
These genes are involved in different aspects of brain health. TREM2 plays a role in the brain’s immune response, affecting how well immune cells clear debris and damaged proteins. SORL1 is involved in directing proteins through cells, helping to route amyloid precursor protein away from the pathway that produces harmful amyloid-beta. ABCA7 helps transport fats across cell membranes, a process critical for brain cell function. When any of these genes carry damaging variants, the brain’s ability to manage amyloid buildup or respond to damage is compromised.
No single one of these genes has the outsized impact of APOE e4, but collectively they help explain why Alzheimer’s risk varies so much between individuals, even those with similar APOE profiles.
The Chromosome 21 Connection
One of the clearest demonstrations that genetics drive Alzheimer’s comes from people with Down syndrome, who carry three copies of chromosome 21 instead of the usual two. The APP gene, which produces the amyloid precursor protein, sits on chromosome 21. Having an extra copy means the brain produces more amyloid-beta from birth, and virtually all people with Down syndrome develop Alzheimer’s brain pathology by middle age.
The proof is remarkably clean. Rare individuals with Down syndrome who, due to the specific nature of their chromosomal duplication, have only two copies of the APP gene do not develop Alzheimer’s dementia, even past age 60. This confirms that the extra copy of APP alone is sufficient to drive the disease, independent of the other genes on chromosome 21.
What the 70% Heritability Estimate Actually Means
When researchers say Alzheimer’s is “70% heritable,” they’re describing how much of the variation in risk across a population can be attributed to genetic differences. This doesn’t mean that 70% of your personal risk is genetic and 30% is lifestyle. Heritability is a population-level statistic, and it shifts depending on the environment. In a population where everyone smoked and never exercised, the environmental contribution would be more uniform, and the heritability estimate would appear higher, even though the environment was clearly contributing to disease.
What this means practically: genetics play a large role, but they operate within a context. The same gene variants may have different effects depending on cardiovascular health, physical activity, education, sleep quality, and other factors that influence brain resilience over a lifetime.
Having a Parent With Alzheimer’s
If a parent developed Alzheimer’s after age 65, your risk is higher than the general population’s, but it’s not a foregone conclusion. The increased risk comes primarily from inheriting common susceptibility variants like APOE e4, along with dozens of smaller-effect gene variants. It does not follow the 50/50 inheritance pattern seen in early-onset familial cases.
The picture changes if multiple close relatives developed Alzheimer’s before age 65. That pattern raises the possibility of an autosomal dominant mutation, and genetic counseling can help determine whether testing makes sense. For families with typical late-onset Alzheimer’s in one or two older relatives, the genetics are real but diffuse, spread across many variants that each contribute a small amount to risk. In those cases, the modifiable risk factors, things like physical activity, hearing loss management, blood pressure control, and social engagement, become the most actionable part of the equation.